Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.

Illumina's (ILMN) GRAIL, Intermountain Healthcare Expand Tie-Up

Study will evaluate whether blood-based testing can inform oncology providers about genetic variations within a patient's cancer, which may influence choice of treatment based on cancer stage and type SAN DIEGO , May 18, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health Network (AHN), an integrated health system serving the Western Pennsylvania area, today announced a collaboration to evaluate the impact of in-house comprehensive genomic profiling (CGP) to enhance patient care. The collaboration will assess the value of in-house testing for both tissue and blood samples, versus sending those samples externally, and whether this approach may benefit cancer patients and the broader healthcare system.

Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care

MENLO PARK, Calif. & SALT LAKE CITY--(BUSINESS WIRE)-- #DetectCancerEarly--Intermountain Healthcare will offer Galleri®, GRAIL's multi-cancer early detection blood test, as a complement to existing single cancer screenings.

GRAIL and Intermountain Healthcare Expand Partnership to Offer Galleri® Multi-Cancer Early Detection Blood Test to Eligible Patients in Utah

An analysis of 2 million Medicare beneficiaries establishes the cost of cancer by stage and time since diagnosis for 17 common cancers. The later the stage at diagnosis, the higher the cost, and this cost difference lasts for at least five years after diagnosis.

Comprehensive Study Establishes Cost of Late Detection and Treatment of Cancer

A jury in the U.S. District Court for the District of Delaware rendered a verdict that Illumina Inc (NASDAQ: ILMN) willfully infringed the U.S. Patent Nos. 9,222,132 and 10,662,473 owned by Complete Genomics Inc. The jury awarded approximately $334 million to CGI in past.

Why Illumina Shares Are Plunging Today?

A Delaware jury on Friday ordered Illumina Inc to pay more than $333 million to a U.S. unit of Chinese genetic analysis company BGI Genomics after finding that Illumina's DNA-sequencing systems infringed two patents.

Illumina ordered to pay Chinese company $333 million in gene-sequencing patent case

Illumina (ILMN) ended the first quarter with better-than-expected earnings and revenues on strength in Core Illumina and the GRAIL businesses driving the top line.

Illumina (ILMN) Q1 Earnings Beat Estimates, Gross Margin Down

Illumina, Inc. (NASDAQ:ILMN ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Salli Schwartz - Vice President, Investor Relations Francis deSouza - President & Chief Executive Officer Sam Samad - Chief Financial Officer Conference Call Participants Dan Brennan - Cowen & Company Dan Arias - Stifel, Nicolaus Mike Ryskin - Bank of America Tejas Savant - Morgan Stanley Kyle Mikson - Canaccord Genuity David Westenberg - Piper Sandler Puneet Souda - SVB Leerink Patrick Donnelly - Citi Vijay Kumar – Evercore John Sourbeer - UBS Jack Meehan - Nephron Research Operator Good day, ladies and gentlemen, and welcome to the First Quarter 2022 Illumina Earnings Conference Call. At this time, all participants are in listen-only mode.

Illumina, Inc. (ILMN) CEO Francis deSouza on Q1 2022 Results - Earnings Call Transcript

Illumina (ILMN) delivered earnings and revenue surprises of 22.99% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) Q1 Earnings and Revenues Beat Estimates

Illumina crushed earnings forecasts on Thursday, though the next-generation DNA sequencer just met sales views. Illumina stock was unchanged.

DNA Giant Illumina Smashes Profit Views, Though Sales Just Meet

Revenue of $1.22 billion for Q1 2022, up 12% from Q1 2021 Earnings per diluted share (diluted EPS) of $0.55 for Q1 2022, compared to $1.00 for Q1 2021 Non-GAAP diluted EPS of $1.07 for Q1 2022, compared to $1.89 for Q1 2021 Reiterating full year revenue guidance of 14-16% growth from fiscal year 2021 Expect diluted EPS of $2.33 to $2.53 for fiscal year 2022 Reiterating non-GAAP diluted EPS guidance of $4.00 to $4.20 for fiscal year 2022 SAN DIEGO , May 5, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2022, which include consolidated financial results for GRAIL. "Illumina maintained strong momentum in the first quarter, particularly across oncology therapy selection, genetic disease testing, and pathogen surveillance," said Francis deSouza, Chief Executive Officer.

Illumina Reports Financial Results for First Quarter of Fiscal Year 2022

First-of-its-kind partnership will identify drug targets and accelerate novel therapy development using genomics and artificial intelligence SAN DIEGO , May 5, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Deerfield Management, a healthcare investment management firm, today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs. The partnership aims to leverage genomic tools and genetic knowledge to select programs with a higher probability of success in order to lower research and development costs and accelerate the approval of cutting-edge therapies.

Illumina and Deerfield Management partner to accelerate drug development

Shares are near a 52-week low, but is that cheap enough?

2 Reasons to Buy Illumina, and 1 Reason to Sell

QIAGEN

QGEN vs. ILMN: Which Stock Is the Better Value Option?

QGEN or ILMN: Which Is the Better Value Stock Right Now?

Hannover Medical School study will evaluate the use of whole-genome sequencing to show positive impact of earlier diagnosis and treatment for children with suspected genetic disorders SAN DIEGO , April 25, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced an agreement with Germany's Hannover Medical School (Medizinische Hochschule Hannover (MHH)) to implement the use of whole-genome sequencing (WGS) in critically ill children suspected of having a genetic or rare disease. The project, led by the Department of Human Genetics at MHH, will evaluate the use of WGS in neonatal and pediatric intensive care unit settings to show the positive impact of earlier diagnosis and treatment for hospitalized children.

Illumina Supports Leading German Hospital to Accelerate Genetic Disease Diagnosis in Critically Ill Children

Investors are optimistic about Illumina's (ILMN) strategic collaborations and strong international sales.

Here's Why You Should Hold on to Illumina (ILMN) Stock For Now

SAN DIEGO , April 14, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it will issue results for the first quarter 2022 following the close of market on Thursday, May 5, 2022.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022

Regulatory complications are raising the legal expenses for Illumina (ILMN), thereby building pressure on the bottom line.

Illumina (ILMN) Hurt by Rising Costs, Tough Competition

Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.

Illumina (ILMN) Launches Genomic Solution Hub in Brazil

Regional Solution Center in São Paulo, Brazil will enable customer access to next-generation sequencing training and expertise to improve patient outcomes  SAN DIEGO , April 12, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of its new state-of-the-art Solution Center in São Paulo, Brazil. The choice to bring the facility to Brazil reflects an increasing demand for and interest in clinical genomics, as well as Illumina's longstanding commitment to expanding global access to genomics in Latin America.

Illumina Expands Access to Genomics in Latin America through New State-of-the-Art Solution Center

SAN DIEGO , April 11, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of John Frank as the Company's Chief Public Affairs Officer (CPAO). Frank joins Illumina on April 18 from Microsoft Corporation; he will report to Chief Executive Officer Francis deSouza.

John Frank Joins Illumina as Chief Public Affairs Officer

COVID-19 crippled the sales of major players in life-science technology.

Illumina: A Good Long-Term BioTech Investment

Illumina's base business is running at peak performance. Illumina's Chemistry X promises to launch its business onto a whole new trajectory.

Chemistry X, Infinity, GRAIL: The New Illumina Is A Buy

Report highlights contributions of genomics to advances in public health and overall health of our planet SAN DIEGO , April 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today released its annual Corporate Social Responsibility (CSR) Report, highlighting the company's 2021 environmental, social, and governance (ESG) program and commitment to human health. The report details Illumina's role as a champion for patients, communities, people, and the planet.

Illumina Releases Annual Corporate Social Responsibility Report

This gene-sequencing leader looks poised to benefit from a pair of long-term trends.

News for Illumina Stock (ILMN)